Antimicrobial Peptides: Novel Source and Biological Function With a Special Focus on Entomopathogenic Nematode/Bacterium Symbiotic Complex

The rapid emergence of multidrug resistant microorganisms has become one of the most critical threats to public health. A decrease in the effectiveness of available antibiotics has led to the failure of infection control, resulting in a high risk of death. Among several alternatives, antimicrobial peptides (AMPs) serve as potential alternatives to antibiotics to resolve the emergence and spread of multidrug-resistant pathogens. These small proteins exhibit potent antimicrobial activity and are also an essential component of the immune system. Although several AMPs have been reported and characterized, studies associated with their potential medical applications are limited. This review highlights the novel sources of AMPs with high antimicrobial activities, including the entomopathogenic nematode/bacterium (EPN/EPB) symbiotic complex. Additionally, the AMPs derived from insects, nematodes, and marine organisms and the design of peptidomimetic antimicrobial agents that can complement the defects of therapeutic peptides have been used as a template.


INTRODUCTION
Antimicrobial peptides (AMPs) are small molecules that generally consist of 10-50 amino acids and are highly conserved in a wide range of species, including insects, nematodes, microbes, and mammals. AMPs serve as an essential component of the body's immune system and defend against exogenous pathogens. They possess significant structural variations in the α-helices, β-strands with one or more disulfide bridges, loop, and extended structures associated with their broad-spectrum activities (Hancock, 2001;Pushpanathan et al., 2013). Other important factors associated with the functional activities of AMPs are size, hydrophobicity, charge, amphipathic stereo-geometry, and peptide self-association to the biological membrane (Nissen-Meyer and Nes, 1997;Marcos and Gandía, 2009;Pushpanathan et al., 2013). AMPs can be considered potential drug candidates to treat pathogenic microorganisms due to their broad-spectrum activity, lesser toxicity, decreased resistance development by the target cells, and capability to modulate the host immune response (Hancock and Patrzykat, 2002;Xu et al., 2019). AMPs can ameliorate the drug-resistant crisis and associated toxicity with conventional AMP drugs and also can be employed as an alternative to antibiotics (Lewies et al., 2019). They exhibit several similarities to antibiotics, such as killing microbial cells and targeting a broad spectrum of pathogens, including antibiotic resistance.
Moreover, compared to antibiotics, AMPs have unique epitopes that serve as protease recognition sites, thereby less likely to be targeted by the protease (Zasloff, 2002;Lai and Gallo, 2009). Different mechanisms, such as inhibition of gene expression or protein synthesis, inhibition of cell wall synthesis, or delocalization of bacterial cell surface proteins are commonly employed by the AMPs (Baltzer and Brown, 2011). Most of the AMPs are cationic and capable of adapting to amphipathic conformations. This helps them interact with the negatively charged bacterial cell wall and integrate it into the lipid bilayers (Haney et al., 2017;Zharkova et al., 2019). The success of AMPs against multidrug-resistant pathogens is due to the widescale multitargeted action (Zharkova et al., 2019). They are also active at lower minimum inhibitory concentrations (MICs) as compared to antibiotics. AMPs demonstrate higher killing effects and show a narrower mutation-selection window, accounting for the less likely development of resistance to AMP (Fantner et al., 2010;Yu et al., 2018). They are also active against biofilmproducing antibiotic-resistant microbes and induce non-opsonic phagocytosis. However, the combined use of AMPs with other antimicrobial compounds such as specific antibiotics may play a vital role against multidrug-resistant pathogens and associated adverse health conditions. In addition, some AMPs have been identified to exhibit antiviral activities (Chia et al., 2010;Van Der Does et al., 2010;Chung and Kocks, 2011;Steckbeck et al., 2014;Elnagdy and AlKhazindar, 2020). The AMPs play an essential role in modulating immunogenic activities, improving wound healing, enhancing chemokine production, exhibiting anti-inflammatory properties, regulating epithelial cell differentiation, and modulating angiogenesis (Koczulla and Bals, 2007;Mahlapuu et al., 2016;Otvos, 2016;Patrulea et al., 2020; Figure 1). Nowadays, scientists are participating in developing enhanced AMPs with novel modes of actions to replace or complement traditional antibiotics to treat various diseases (Morikawa et al., 1992;Wang et al., 2016). So far, 3257 AMPs have been reported from six kingdoms (bacteria, archaea, fungi, protists, plants, and animals) in the Antimicrobial Peptide Database 1 (Wang et al., 2016). This review provides insights into developing different AMPs from novel sources and their multifunctional properties and elaborates their future prospects (Figure 2). Particular focus has been given to the AMPs in bacteria that form a symbiotic relationship with 1 http://aps.unmc.edu/AP/main.php/ the entomopathogenic nematodes (EPNs), displaying varied modes of actions.

AMPS IN INSECTS
Insects represent the largest class in the animal kingdom and are found in most of the biological niches. One of the critical features of their successful adaptation is their resistance to various pathogens. The AMPs play a critical role in innate immunity against insect pathogens (Bulet et al., 1999). They produce a large number of AMPs that varies between species, ranging from 50 (Harmonia axyridis) to 0 (Hermetia illucens) (Gerardo et al., 2010;Vilcinskas, 2013;Vogel et al., 2018). Cecropin, the first insect AMP, was isolated and characterized from Hyalophora cecropia (Steiner et al., 1981). Since then, many insect AMPs have been reported, which are mainly classified into three groups based on the sequence and structural features, i.e., linear peptides with α-helices that lack cysteine residues and cyclic peptides containing cysteine residues and peptides with an overexpression of proline and glycine residues (Hetru, 1998;Bulet et al., 1999). The most explored insect AMPs are defensin, cecropin, drosocin, attacin, diptericin, ponericin, drosomycin, and metchnikowin. However, it is expected that insects may have more AMPs with novel modes of action (Mylonakis et al., 2016).
However, limited reports are available on antifungal peptides in insects such as drosomycin from D. melanogaster, termicin from termites, heliomicin from H. virescens, and gallerimycin peptide from G. mellonella (Fehlbaum et al., 1994;Da Silva et al., 2003;Schuhmann et al., 2003). The antifungal peptide drosomycin is active against fungal pathogens, whereas thanatin is effective against a broad range of β-lactamase-producing E. coli (Bulet et al., 1999;Hou et al., 2011). Xu et al. (2019) reported a novel Moricin (Px-Mor) from the diamondback moth that showed a broad-spectrum activity against GPB, GNB, and fungi, including the opportunistic human pathogen Aureobasidium pullulans. They suggested that Px-Mor can be used as a potential topical antimicrobial agent (Xu et al., 2019). These results indicate the importance of insect-derived AMPs against pathogens and could be further employed against multidrug-resistant pathogens or in combination with existing antibiotics ( Table 1).

AMPS IN NEMATODE
Antimicrobial peptides are produced by microorganisms associated with insect symbioses and play a significant role in maintaining the symbiotic microbe in specific anatomical compartments (Ovchinnikova et al., 2004;Tasiemski et al., 2015). A lot of the literature have highlighted the EPN/entomopathogenic bacterium (EPB) symbioses. Nematodes are specialized organisms with the ability to adapt both free-living and parasitic lifestyle in different environments. Nematodes also serve as a novel invertebrate model to study innate immunity and host-pathogen interactions (Kurz and Tan, 2004;Nicholas and Hodgkin, 2004). EPNs and their associated bacteria have evolved with several defense mechanisms to elude and counteract the host (insect) immune responses Brivio and Mastore, 2020). The nematode Steinernema carpocapsae can produce proteolytic secretions that can interfere with the host immune system in S. feltiae, S. glaseri, and G. mellonella (Balasubramanian et al., 2010;Chaubey and Garg, 2019). Similarly, the surface proteins of S. glaseri protect from encapsulation by the host immune system of Popillia japonica (Wang and Gaugler, 1999;Chaubey and Garg, 2019). It has also been reported that symbiotic bacteria and nematode cooperate to overcome the host immune response. Many defense molecules are produced as immune effectors against various microbial infections (Bulet et al., 2004). The AMP cecropins are found in the worm Ascaris suum (cecropin-P1, cecropin-P2, cecropin-P3, and cecropin-P4), a parasite inhabiting the intestine of pigs. These short AMPs, rich in serine residues, are stabilized by the disulfide bonds and contain potential antimicrobial activities against BPB (S. aureus, B. subtilis, Micrococcus luteus) and GNB (Pseudomonas aeruginosa, Salmonella typhimurium, Serratia marcescens, and E. coli) and are less effective against fungi (Saccharomyces cerevisiae, C. albicans) (Andrä et al., 2001;Andersson et al., 2003;Pillai et al., 2005;Bruno et al., 2019). Cecropin P1-like sequences were also identified in two other species, i.e., Ascaris lumbricoides and Toxocara canis (Pillai et al., 2005).
Defensins are the most studied AMPs in nematodes. Ascaris suum antibacterial factors (ASABFs) was the first nematode defensin identified in C. elegans. They are short AMPs with eight cysteine residues that form four disulfide bonds except for ASABF-6Cys-α (Minaba et al., 2009;Tarr, 2012). These peptides are primarily active against GPB, especially the common pathogen S. aureus. However, it is less effective against GNB and yeast (Tarr, 2012). A recent study by Lim et al. (2016) reported two novel C. elegans AMPs (NLP-31 and Y43C5A.3) that exhibit antimicrobial activity against Burkholderia pseudomallei, the causative agent of melioidosis, by interfering with DNA synthesis. They also revealed that these AMPs might act by modulating host cytokine production to interfere with the inflammatory response, and modifications could enhance anti-B. pseudomallei activities (Lim et al., 2016).

AMPS LINKED WITH EPN/EPB SYMBIOTIC COMPLEX
Several bacterial genera belonging to the Enterobacteriaceae family are mutualistically associated with the EPNs (Boemare, 2002). These EPNs, with their symbiotic bacteria, are lethal to many soil insects, as they synthesize diverse secondary metabolites, including small AMPs. These nematode-associated microbes exist in two distinct phases: phase 1, where they are generally associated with the nematodes, and phase 2, where they may also colonize with the nematode. However, they have never been reported to be associated with the naturally occurring nematodes. Both the phases have distinguished physiological, biochemical, and behavioral features; also phase 1 is considered more virulent than phase 2 (Akhurst et al., 1990;Volgyi et al., 1998;Abdel-Razek, 2002;Sugar et al., 2012). During the infective juvenile (IJ) stage, the nematodes enter inside the insects by piercing the body wall or via natural openings and releasing these bacteria inside the hemocoel. They reproduce exponentially, producing bioactive compounds with broadspectrum antimicrobial activities (Sanda et al., 2018). They provide nutrients to the nematodes and protect them from environmental predators such as bacteria and fungi. They also compete for nutrition with other microbes, including the saprophytic soil microbes and the bacteria present in the insect gut or cuticle of the nematode. The elimination of the competitors is facilitated by the production of colicin E3-type killer proteins, insect toxin complexes, phage-derived bacteriocins, and several secondary metabolites (Thaler et al., 1995;Ffrench-Constant and Waterfield, 2006;Singh and Banerjee, 2008;Bode, 2009;Piel, 2009). The presence of high content of non-ribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) genes facilitates them to produce novel and new bioactive molecules (Tobias et al., 2017). These bioactive molecules disrupt the insect's metabolic and functional properties, leading to septicemia (Khandelwal and Banerjee-Bhatnagar, 2003;Tran and Goodrich-Blair, 2009;Ellis and Kuehn, 2010;. Nematodes also play a significant role in the pathogenicity of the nematobacterial complex (Han and Ehlers, 2000;Chang et al., 2019). The EPNs, along with the mutualistic bacteria, kill their host within 48−72 h (Forst and Nealson, 1996). These features are now being exploited for the biological control of pests (Brivio and Mastore, 2018).
The bacterial genus Xenorhabdus is often found in close association with EPNs of the family Steinernematidae (Webster et al., 2002). Xenorhabdus synthesizes and releases antibiotic compounds in the host hemocoel that suppresses the microbial competitors, thereby manipulating the environment to promote growth, proliferation, and nematode development (Vallet-Gely et al., 2008;Richards and Goodrich-Blair, 2009;Gaugler, 2018). The antimicrobial compounds produced by these bacterial genera are highly toxic to the insect but not toxic to the nematodes. Various surface structures such as pili/fimbriae, flagella, and the outer membrane vesicles (OMVs) present in the Xenorhabdus interact with the host and promote adhesion and invasion of the host tissues. They also promote larvicidal activity by releasing proteases, lytic factors, and phospholipase C .
The cyclic peptide-antimicrobial-Xenorhabdus (PAX) lipopeptides, obtained by the fermentation of the X. nematophila F1 strain, exhibit significant activity against plants and human fungal pathogens and moderately effective against a few bacteria and yeast (Gualtieri et al., 2009). Two novel AMPs GP-19 and EP-20 from the bacterial strain X. budapestensis NMC-10. GP-19 exhibited inhibitory activity mainly against bacteria, while EP-20 was highly effective against plant pathogens. The synthetic GP-19 and EP-20 peptide exhibited inhibitory activities against the fungal pathogen Verticillium dahlia and Phytophthora capsici with EC 50 values of 17.54 and 3.14 µg/ml, respectively (Xiao et al., 2012).
Nematophins, from X. nematophila YL001, inhibit mycelial growth of Rhizoctonia solani and Phytophthora infestans with an EC 50 value of 40.00 and 51.25 µg/ml, respectively, and can be employed as a potential biopesticide in the agriculture sector . Similarly, the novel peptide, xenoamicin, tridecadepsipeptides with hydrophobic amino acids, from the entomopathogenic X. doucetiae DSM 17909 and X. mauleonii DSM 17908 was effective against Plasmodium falciparum (Zhou et al., 2013).
Another dipeptide xenobactin was isolated from Xenorhabdus sp., strain PB30.3, and szentiamide from X. szentirmaii. Both AMPs are active against P. falciparum and have moderately effective against T. brucei rhodesiense and Trypanosoma cruzi (Nollmann et al., 2012;Grundmann et al., 2013). Similarly, the depsipentapeptide chaiyaphumine A from Xenorhabdus sp. PB61.4 was effective against P. falciparum (IC 50 of 0.61 µM) and other protozoal tropical disease-causing agents (Grundmann et al., 2014). Xenorhabdus indica can produce depsipeptides and lipodepsipeptides with an additional fatty acid chain linked to one of the amino acids, also called taxlllaids (A-G), and exhibits antiprotozoal activity (Kronenwerth et al., 2014). Taken together, these reports suggest that the mutualistic association between Xenorhabdus and Steinernematidae could serve as a potential source for novel AMPs against bacteria, fungi, and protozoal disease-causing agents.
The bacterium Photorhabdus spp. forms a symbiotic relationship with the EPNs of the genus Heterorhabditis (Gerrard et al., 2006). They cause pathogenicity in most insects post invading the hemolymph (Boemare et al., 1997). Genomic analysis of Photorhabdus can interpret the relation between pathogenesis and symbiosis, thereby providing vital information for the development of biocontrol agents. The genomic sequence of P. luminescens subsp. laumondii strain TT01 revealed several genes that encode toxins, hemolysins, adhesins, hemolysins, proteases, lipases, and a wide array of antibiotics. Two identified protein, PirA and PirB, exhibit similarity to both δ-endotoxins (B. thuringiensis) and a developmentally regulated protein from a beetle (Leptinotarsa decemlineata) (Duchaud et al., 2003;Waterfield et al., 2005). Research on the larvicidal activity of Photorhabdus sp. showed that Photorhabdus insect-related (Pir) protein is associated with high toxicity against the primary vector of dengue virus A. aegypti and Aedes albopictus (Ahantarig et al., 2009). These novel insecticidal proteins could further be exploited to develop alternative agents to control insect pests. Genomic analysis of P. luminescens subsp. laumondii strain TT01 indicates the presence of several enzymes associated with the secondary metabolite biosynthesis. The genomic sequence analysis identifies biosynthetic gene clusters associated with the synthesis of linear or cyclized peptides, lipopeptides, or depsipeptides; NRPS; unusual fatty acid synthase or a FAS/PKS hybrid; and siderophore biosynthesis (Bode, 2009). Photorhabdus sp. also produces numerous antimicrobials such as isopropyl stilbene, ethylstilbenes, anthraquinones (AQs) photobactin, ethyl stilbene, epoxystilbene, and ulbactin E (Li et al., 1995;Webster et al., 2002;Bode, 2009). The bioactive compounds exhibit a broad range of antimicrobial activities. Photorhabdus antibacterial compounds include trans-stilbenes and anthraquinone pigments (Boemare and Akhurst, 2002) that have enthralled substantial interest in the agronomic and pharmaceutical sectors (Webster et al., 2002;Hazir et al., 2016). Phthalic acid or 1,2-benzene dicarboxylic acid purified from Photorhabdus temperata M1021 exhibits an antibacterial activity with MIC values of 0.1 and 0.5 M (Ullah et al., 2014), benzaldehyde exhibits an antibacterial activity with MIC values of 6 and 10 mM, and antifungal activity with MIC values between 8 and 10 mM (Ullah et al., 2015). P. temperata subsp. temperata inhibits the growth of 10 strains of drug-resistant bacteria (Muangpat et al., 2017), including S. typhimurium KCTC 1926 and M. luteus KACC 10488 (Jang et al., 2012). Therefore, Photorhabdus spp. can be a suitable biocontrol agent in drug industries. AMPs from nemato-bacterial complexes with their inhibitory concentrations are shown in Table 2.

THE TARGETS AND MECHANISM OF ACTION OF AMPS DERIVED FROM NEMATOBACTERIAL COMPLEXES
The AMPs from Xenorhabdus spp. and Photorhabdus spp. are non-lethal to nematode but toxic to insect pathogens and other opportunistic microorganisms with unique targets and modes of action. This section highlights some of the recently identified AMPs from EPB with novel modes of action, namely, nematophin, odilorhabdin, darobactin, and photoditritide (Figure 3).

Odilorhabdin
This is a new class of AMP with broad-spectrum activity encoded by the enzymes (of NRPS gene cluster) of X. nematophila. This peptide binds to the decoding center of the small ribosomal subunit, leading to faulty coding procedure and prohibits non-cognate aminoacyl-tRNAs binding (Pantel et al., 2018). Odilorhabdin can directly bind with the new site on 16S rRNA ( Figure 3B) and with the anticodon loop of the A-site aminoacyl-tRNA concurrently, resulting in the precision of translation decreased. At very high concentrations, odilorhabdin hinders the ribosome movement on mRNA (Pantel et al., 2018). Studies reported that odilorhabdin acts against Gram-negative and Gram-positive bacterial pathogens, including carbapenem-resistant Enterobacteriaceae, which strain especially shows resistance toward many classes of available antibiotics and causes severe infections with a 50% mortality rate (van Duin et al., 2013).

Darobactin
It is a novel peptide antibiotic produced by Photorhabdus khanii HGB1456 (Imai et al., 2019) that is effective against several Gram-negative drug-resistant pathogens. Instead of targeting the enzymes, darobactin targets outer membrane chaperone BamA (Figure 3C), catalyzing the insertion and folding of β-barrel outer membrane proteins in many Gram-negative pathogens. As the target of darobactin is a cell surface protein, there is no permeability obstacle encountered (Imai et al., 2019). No antibiotics were reported to act on the two surface proteins, namely, BamA and LptD, present on the GNB; therefore, darobactin could act as a potential drug candidate due to its distinctive sizeable molecular structure fused rings and unusual cell surface target (Konovalova et al., 2017).

Photoditritide
Photoditritide is the first non-proteinogenic peptide reported from P. temperata Meg1 through promoter exchange (Maglangit et al., 2021). Photoditritide 19 consists of two tyrosines, two homo-arginines, and two tryptophans (Bode et al., 2015). It is effective against E. coli (MIC = 24 µM), M. luteus (MIC = 3.0 µM), and antiprotozoal activity against P. falciparum (IC 50 = 27 µM), T. cruzi (IC 50 = 71 µM), and T. brucei rhodesiense (IC 50 = 13 µM) (Bode et al., 2015). The increasing evidence of antibiotic resistance is a serious issue. Drug-resistant pathogens develop new resistance mechanisms and interfere in the treatment of common infections. Moreover, multidrug resistance pathogenic strains have developed tolerance against most of the available antibiotics. Researchers searching for novel sources of antimicrobial agents through synthetic compound library screening have mostly failed to get efficient antimicrobial agents (Payne et al., 2007). Therefore, exploiting new natural antimicrobial sources to fill the research gap in antimicrobial drug discovery is a promising approach. Most of the antibiotics used to date belong to soil actinomycetes. The present review aims to compile novel natural sources, highlighting the unnoticed and ignored sources to identify new AMPs with a unique mode of action. The marine ecosystem presents a vast repository of microorganisms, invertebrates, and vertebrates that produce various natural products and AMPs with the perspective of treating several infectious diseases (Bertrand and Munoz-Garay, 2019).

MARINE-DERIVED ANTIMICROBIAL PEPTIDES
The marine ecosystem encompasses an unprecedented variety of organisms that have shown remarkable contribution in discovering and developing novel biomolecules, nutraceuticals, and secondary metabolites that pave the way to produce antimicrobial agents (Malve, 2016;Sekurova et al., 2019; Figure 1). AMPs derived from marine sources are novel and revolutionary therapeutic agents with distinctive pharmacological properties such as antimicrobial, antiproliferative, antioxidant, anticoagulant, antihypertensive, antidiabetic, and antiobesity properties (Jo et al., 2017).

Antimicrobial Peptides Derived From Marine Invertebrates
Marine invertebrates produce AMPs to activate innate immune machinery to recognize, neutralize, and eliminate invading pathogens (Loker et al., 2004). A wide variety of corals produce structurally unique bioactive metabolites that can serve as significant novel compounds in drug development against various human diseases. For example, the marine fungus Simplicillium sp. associated with soft coral Sinularia sp. synthesizes five new peptides, including Sinularia peptides A-E. These bioactive AMPs exhibit significant antimicrobial activity against Mycobacterium tuberculosis, Colletotrichum asianum, and Pyricularia oryzae Cav. Mollusks such as Mytilus edulis, Ruditapes decussatus, and oyster Mytilus galloprovincialis produce AMPs such as myticins and mytilin. A cyclic hexapeptide, cyclo-(Gly-Leu-Val-IIe-Ala-Phe), bacicyclin isolated from Bacillus sp. associated with M. edulis, exhibits antibacterial activities against clinically relevant bacterial strains such as S. aureus and Enterococcus faecalis (Wiese et al., 2018;Zanjani et al., 2018). AMPs derived from marine invertebrates can modulate the lifecycle of bacterial biofilm and also inhibit biofilm formation. Crustin, an antibacterial protein, consists of alanine or threonine, glycine, and glutamine residues at their cleavage site and is derived from the hemolymph of crustaceans (Destoumieux-Garzón et al., 2016). It effectively inhibits biofilm formation of various antibiotic-resistant bacterial strains, including B. pumilis and B. thuringiensis and also is effective against Aeromonas hydrophila and E. coli (Rekha et al., 2018;Sivakamavalli et al., 2020). A novel antibacterial peptide named PcnAMP, extracted from Procambarus clarkia (Pcn) (a red swamp crayfish), exhibits a significant inhibitory effect against Gram-positive and GNB strains such as S. aureus and M. luteus (Zhao B. R. et al., 2020). AMPs from ascidian Didemnum sp. exhibit an antibacterial effect against human pathogens E. faecalis, S. marcescens, S. typhimurium, and S. aureus at MICs of 2.30, 2.17, 2.05, and 1.95 µg/ml, respectively (Arumugam et al., 2020). The AMPs halocyntin and papillosin from tunicate H. papillosa exhibit antibacterial activity against M. luteus and E. coli (Palanisamy et al., 2017). A novel AMP myticusinbeta isolated from the mantle of Mytilus coruscus exhibits a broad range of antibacterial activity and acts as a substitute to antibiotics (Oh et al., 2020). Therefore, the diverse forms of marine invertebrates act as natural reservoirs for novel AMPs, which can be exploited for the treatment of various microbial infections (Thoms et al., 2007;Destoumieux-Garzón et al., 2016; Table 3).

Antimicrobial Peptides From Marine Microorganisms
Marine microbial systems are the significant resources of AMPs with unique pharmacological features, including antimicrobial, cytostatic, animal growth, immunosuppressant, antiviral, antimalarial, antiparasitic, promoters, and insecticides activities (Semreen et al., 2018). AMPs extracted from symbiotic marine microorganisms exhibit enhanced broad-spectrum antimicrobial activity. These natural compounds are now being exploited to resolve the microbial drug-resistance problem. Hyporientalin A, an anti-Candida peptaibol, a moronecidin-like peptide from Trichoderma orientale strains, symbiotic fungi of Mediterranean marine sponge Cymbaxinella damicornis, inhibits the growth of clinical isolates of C. albicans, Gram-positive and Gram-negative bacteria (Touati et al., 2018). Cyclic lipopeptide Fengycins from marine bacterium B. subtilis (BS155) is effective against the plant-pathogenic fungus Magnaporthe grisea. Host-dependent marine microbes are excellent sources of many active antimicrobial cyclic peptides (e.g., the cyclolipopeptides cyclodysidins A-D). These peptides, secondary metabolites of Streptomyces sp. associated with sponge Dysidea tupha, exhibit broad-spectrum antimicrobial activities (Indraningrat et al., 2016). Different marine gamma-proteobacteria associated with seaweeds, particularly, Pseudomonas sp., are the primary sources in cyclotetrapeptide cyclo-(isoleucyl-prolyl-leucyl-alanyl), cyclic heptapeptide, scopularides A and B, and ogipeptin A-C. These peptides exhibit intense antimicrobial and anthelmintic activities. Ogipeptin is a powerful agent suppressing the immunostimulatory role of lipopolysaccharides present in the cell wall of GNB (Betancur et al., 2019). Similarly, the marine sponge Tethya aurantium associated with fungus Scopulariopsis brevicaulis synthesizes cyclodepsipeptides scopularides A and B that exhibit effective cytotoxic activity against pathogens (Agrawal et al., 2017). New cyclic lipopeptides maribasins A and B from the broth culture of marine microorganism B. marinus exhibit broad-spectrum activities against phytopathogens such as Fusarium oxysporum, Fusarium graminearum, Verticillium alboatrum, Alternaria solani, and R. solani with the MICs of 25-200 mg/ml (Zhang et al., 2010). Additionally, the two new cyclic tetrapeptides, from the marine strain Streptomyces sp., are effective against Burkholderia gladioli and Burkholderia glumae at MIC of 0.068 and 1.1 mM, respectively. Furthermore, tetrapeptide-2 is effective against B. glumae (MIC = 1.1 mM) and fungal phytopathogens (Betancur et al., 2019). Hence, the diversified marine microorganisms prove to be an effective substitute to the existing antibiotics, thereby reducing the probability of antibiotic-resistant pathogens ( Table 3).

Antimicrobial Peptides From Marine Vertebrates
Antimicrobial peptides in marine vertebrates are mainly localized in body fluids, mucous layers, and epithelial surfaces (Edilia Avila, 2017). AMPs participate in body defense mechanisms to eliminate the invading pathogens and enhance physiological and metabolic processes such as toxin neutralization, wound healing, angiogenesis, and iron metabolism. For instance, epinecidin-1 (Epi-1) disrupts the cell membrane of metronidazole-resistant Trichomonas vaginalis and terminates the pathogen with a minimal dose of 62.5 µg/ml. T. vaginalis treated with different concentrations of Epi-1 (62.5, 125, 250, or 500 µg/ml) exhibits 100% growth inhibition (Huang et al., 2019). 3C-terminal peptide tissue factor pathway inhibitor 1 (TFPI-1) from Cyprinus carpio (common carp) exhibits bactericidal effects against M. luteus, S. aureus, and Vibrio vulnificus . Orange-spotted grouper (Epinephelus coioides) derived from AMP EPI is effective against GPB (Su and Chen, 2020). Cysteine-rich Hepcidins (CtHep) from vertebrates such as fish, reptiles, and amphibians can significantly inhibit Streptococcus iniae and A. hydrophila (Shirdel et al., 2019). Marine betta fish Betta splendens produce four families of AMPs, including defensins, piscidins, hepcidins, and LEAP-2, which vigorously suppress the growth of fungi, bacteria, virus, and parasites (Amparyup et al., 2020). A short novel peptide synthesized from the core region of the LCNKL2 of a marine fish Larimichthys crocea inhibits S. aureus and Vibrio harveyi . Antibacterial activity of piscidin-5 like AMP has been reported from L. crocea (Pan et al., 2019). Therefore, AMPs are essential to induce adaptive response and participate in a vertebrate's metabolic and reproductive processes ( Table 3).

CONCLUSION
The exponentially increasing cases of antibiotic resistance requires the introduction of novel and alternative drug molecules. Insects, nematodes, insect-nematode-bacterial associations and marine organisms could be promising sources for natural AMPs to address the challenges of multidrug-resistant infections. The conventional method of overmining natural antibiotic sources has failed to develop new drugs to overcome drug resistance. Genomic analysis indicates the presence of several gene clusters for the novel secondary metabolite biosynthesis. The exploitation of these secondary metabolites might lead to the discovery of potential antimicrobial compounds. This review thereby highlights the symbiotic bacteria-EPN complexes as prospective antimicrobial peptide sources and opens the window to new sources of intervention and invention of natural bioactive compounds to combat antimicrobial resistance. Further research is required to understand the metabolic pathways to optimize the conditions for large-scale production and commercialization of these drug molecules as adequate substitutes.

AUTHOR CONTRIBUTIONS
SD, FJ, and XX conceptualized the manuscript. SD, AP, and CM drafted the manuscript. AP was responsible for preparing the figures in the manuscript. FJ, NS, SD, AP, and CM assisted in revising the manuscript. All authors contributed to the article and approved the submitted version.